Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
The latest omicron subvariants—especially the currently dominant BA.4 and BA.5 forms—are even better at eluding vaccines and most treatments, find researchers at Columbia University.